ClinicalTrials.govpublic full text
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
atrial fibrillation, heart failure with preserved ejection fraction (hfpef), tirzepatide, gip/glp-1 receptor agonist, obesity, hfpef, interventional, phase4
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 863868
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.